477 related articles for article (PubMed ID: 33959589)
1. From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation.
Cecchini C; Pannilunghi S; Tardy S; Scapozza L
Front Chem; 2021; 9():672267. PubMed ID: 33959589
[TBL] [Abstract][Full Text] [Related]
2. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
3. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
Gu S; Cui D; Chen X; Xiong X; Zhao Y
Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
[TBL] [Abstract][Full Text] [Related]
4. Linkers as Game-changers in PROTAC Technology: Emphasizing General Trends in PROTAC Pharmacokinetics for their Rational Design.
Cecchini C; Tardy S; Scapozza L
Chimia (Aarau); 2022 Apr; 76(4):341-345. PubMed ID: 38069776
[TBL] [Abstract][Full Text] [Related]
5. Degraders upgraded: the rise of PROTACs in hematological malignancies.
Casan JML; Seymour JF
Blood; 2024 Mar; 143(13):1218-1230. PubMed ID: 38170175
[TBL] [Abstract][Full Text] [Related]
6. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
[TBL] [Abstract][Full Text] [Related]
7. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
8. An overview of PROTACs: a promising drug discovery paradigm.
Liu Z; Hu M; Yang Y; Du C; Zhou H; Liu C; Chen Y; Fan L; Ma H; Gong Y; Xie Y
Mol Biomed; 2022 Dec; 3(1):46. PubMed ID: 36536188
[TBL] [Abstract][Full Text] [Related]
9. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
Pettersson M; Crews CM
Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855
[TBL] [Abstract][Full Text] [Related]
10. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges.
Yang W; Saboo S; Zhou L; Askin S; Bak A
Drug Discov Today; 2024 Feb; 29(2):103865. PubMed ID: 38154757
[TBL] [Abstract][Full Text] [Related]
11. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
Zhu H; Wang J; Zhang Q; Pan X; Zhang J
Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
[TBL] [Abstract][Full Text] [Related]
12. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
13. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022.
Tamatam R; Shin D
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982263
[TBL] [Abstract][Full Text] [Related]
14. A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy.
Chen X; Shen H; Shao Y; Ma Q; Niu Y; Shang Z
Transl Androl Urol; 2021 Feb; 10(2):954-962. PubMed ID: 33718095
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in targeted protein degraders as potential therapeutic agents.
Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
[TBL] [Abstract][Full Text] [Related]
16. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
[TBL] [Abstract][Full Text] [Related]
17. Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin-Proteasome system.
Xie H; Zhang C
Eur J Med Chem; 2024 Mar; 267():116168. PubMed ID: 38310686
[TBL] [Abstract][Full Text] [Related]
18. Frontiers in PROTACs.
Hughes GR; Dudey AP; Hemmings AM; Chantry A
Drug Discov Today; 2021 Oct; 26(10):2377-2383. PubMed ID: 33872800
[TBL] [Abstract][Full Text] [Related]
19. PROTACs in gastrointestinal cancers.
Chen Y; Yang Q; Xu J; Tang L; Zhang Y; Du F; Zhao Y; Wu X; Li M; Shen J; Ding R; Cao H; Li W; Li X; Chen M; Wu Z; Cho CH; Du Y; Wen Q; Xiao Z
Mol Ther Oncolytics; 2022 Dec; 27():204-223. PubMed ID: 36420306
[TBL] [Abstract][Full Text] [Related]
20. Emerging TACnology: Heterobifunctional Small Molecule Inducers of Targeted Posttranslational Protein Modifications.
Heitel P
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
